MetaCap

Ernexa Therapeutics (ERNA) vs GRI Bio (GRI)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

GRI Bio is the larger company by market cap ($2.4 million vs $2.3 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ERNA-43.10%GRI-39.46%
+7%-19%-45%
Oct 7, 20261 yearNov 20, 2026
ERNA-43.33%GRI-35.63%
+11%-18%-46%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ERNA versus GRI key metrics
MetricERNAGRI
Share price$1.36$1.12
Market cap$2.30M$2.45M
1-day change-16.56%0.00%
P/E ratio (TTM)—0.05
EPS (TTM)$-11.22$20.57
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-14.08M$-11.96M
52-week high$37.50$64.12
52-week low$1.35$1.09
Distance from 52-week high-96.37%-98.25%
Analyst consensusnonenone
Avg. price target upside+2105.88%+1551.79%
Average volume43.90K218.31K
Shares outstanding1.69M2.19M
Employees53
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Ernexa Therapeutics

ERNA stock →

Ernexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of treatment of cancer and autoimmune disease. The company's lead product is ERNA-101, an allogenic pro-inflammatory cytokine (IL-7/IL-15) secreting iMSC for the treatment of ovarian cancer; and ERNA-201, an anti-inflammatory cytokine (IL-10) secreting iMSC for the treatment of rheumatoid arthritis.

Health Care · Biotechnology: Pharmaceutical Preparations · 5 employees

About GRI Bio

GRI stock →

GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis.

Health Care · Biotechnology: Pharmaceutical Preparations · 3 employees

ERNA vs GRI FAQ

Which is bigger, Ernexa Therapeutics or GRI Bio?

GRI Bio (GRI) is larger, with a market capitalization of $2.45M compared with $2.30M for Ernexa Therapeutics (ERNA).

Are Ernexa Therapeutics and GRI Bio in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons